User login
VIDEO: New genetic research could identify Alzheimer’s therapy targets
COPENHAGEN – The National Institutes of Health recently awarded $24 million to eight academic centers to analyze the human genome and identify genes that either increase the risk of Alzheimer’s disease or have a protective effect.
It’s a very exciting time in Alzheimer’s disease genetics, said Marilyn Miller, Ph.D., program director of the National Institute of Aging’s Genetics of Alzheimer’s Disease, Tau, and Hormone Research portfolios in the division of neuroscience.
In a video interview at the Alzheimer’s Association International Conference 2014, Dr. Miller explains the ongoing research and the implications for potential therapies.
Alzheimer’s genetics research resources:
• The Alzheimer’s Disease Sequencing Project.
• The NIA Genetics of Alzheimer’s Disease Data Storage Site.
• The National Plan to Address Alzheimer’s Disease.
• The National Human Genome Research Institute.
On Twitter @naseemmiller
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
COPENHAGEN – The National Institutes of Health recently awarded $24 million to eight academic centers to analyze the human genome and identify genes that either increase the risk of Alzheimer’s disease or have a protective effect.
It’s a very exciting time in Alzheimer’s disease genetics, said Marilyn Miller, Ph.D., program director of the National Institute of Aging’s Genetics of Alzheimer’s Disease, Tau, and Hormone Research portfolios in the division of neuroscience.
In a video interview at the Alzheimer’s Association International Conference 2014, Dr. Miller explains the ongoing research and the implications for potential therapies.
Alzheimer’s genetics research resources:
• The Alzheimer’s Disease Sequencing Project.
• The NIA Genetics of Alzheimer’s Disease Data Storage Site.
• The National Plan to Address Alzheimer’s Disease.
• The National Human Genome Research Institute.
On Twitter @naseemmiller
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
COPENHAGEN – The National Institutes of Health recently awarded $24 million to eight academic centers to analyze the human genome and identify genes that either increase the risk of Alzheimer’s disease or have a protective effect.
It’s a very exciting time in Alzheimer’s disease genetics, said Marilyn Miller, Ph.D., program director of the National Institute of Aging’s Genetics of Alzheimer’s Disease, Tau, and Hormone Research portfolios in the division of neuroscience.
In a video interview at the Alzheimer’s Association International Conference 2014, Dr. Miller explains the ongoing research and the implications for potential therapies.
Alzheimer’s genetics research resources:
• The Alzheimer’s Disease Sequencing Project.
• The NIA Genetics of Alzheimer’s Disease Data Storage Site.
• The National Plan to Address Alzheimer’s Disease.
• The National Human Genome Research Institute.
On Twitter @naseemmiller
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
At AAIC 2014
VIDEO: Children’s psychiatric disorders linked with moms’ fertility problems
MUNICH – Children born to mothers who required fertility treatment had a significantly higher rate of psychiatric disorders, compared with children born to mothers without fertility problems, based on population-wide registry data collected in Denmark.
Although psychiatric disorders occurred a third more often in children born to mothers treated at fertility clinics, this "modest" increase should not deter women with fertility problems from seeking treatment and becoming pregnant, Allan Jensen, Ph.D., said in a video interview at the annual meeting of the European Society of Human Reproduction and Embryology.
The increased risk of psychiatric disorders probably springs from the underlying infertility of these women and damaged genes that they may carry, rather than because of any fertility treatments they received, said Dr. Jensen, a senior researcher at the Danish Cancer Society Research Center, Copenhagen.
Dr. Jensen said that he had no disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @mitchelzoler
MUNICH – Children born to mothers who required fertility treatment had a significantly higher rate of psychiatric disorders, compared with children born to mothers without fertility problems, based on population-wide registry data collected in Denmark.
Although psychiatric disorders occurred a third more often in children born to mothers treated at fertility clinics, this "modest" increase should not deter women with fertility problems from seeking treatment and becoming pregnant, Allan Jensen, Ph.D., said in a video interview at the annual meeting of the European Society of Human Reproduction and Embryology.
The increased risk of psychiatric disorders probably springs from the underlying infertility of these women and damaged genes that they may carry, rather than because of any fertility treatments they received, said Dr. Jensen, a senior researcher at the Danish Cancer Society Research Center, Copenhagen.
Dr. Jensen said that he had no disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @mitchelzoler
MUNICH – Children born to mothers who required fertility treatment had a significantly higher rate of psychiatric disorders, compared with children born to mothers without fertility problems, based on population-wide registry data collected in Denmark.
Although psychiatric disorders occurred a third more often in children born to mothers treated at fertility clinics, this "modest" increase should not deter women with fertility problems from seeking treatment and becoming pregnant, Allan Jensen, Ph.D., said in a video interview at the annual meeting of the European Society of Human Reproduction and Embryology.
The increased risk of psychiatric disorders probably springs from the underlying infertility of these women and damaged genes that they may carry, rather than because of any fertility treatments they received, said Dr. Jensen, a senior researcher at the Danish Cancer Society Research Center, Copenhagen.
Dr. Jensen said that he had no disclosures.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
On Twitter @mitchelzoler
AT ESHRE 2014
Dawn C. Buse, PhD
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Robert Merrill, DDS
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
VIDEO: ‘Improve – but do not abandon – power morcellation’
SILVER SPRING, MD. – Without power morcellation, the number of hysterectomies performed using an open approach would dramatically increase – and the combined mortality from laparoscopic hysterectomy and potential dissemination of leiomyosarcoma would be less than that of open hysterectomy, according to testimony given July 11 at a Food and Drug Administration expert panel meeting.
Dr. Jubilee Brown, director of gynecologic oncology at the Woman's Hospital of Texas, University of Texas M.D. Anderson Cancer Center, Houston, testified at the meeting on behalf of the AAGL, an association that promotes minimally invasive gynecologic surgery. She presented results of a decision analysis suggesting that if all U.S. cases were converted to open hysterectomy from laparoscopic hysterectomy (LH) with morcellation of fibroids, 17 more women each year would die from the open procedure than from the combination LH and morcellation.
"Improve – but do not abandon – power morcellation," Dr. Brown told the FDA Obstetrics and Gynecology Devices Advisory Committee. She discussed her testimony during this video interview.
Dr. Brown said she had no relevant financial conflicts of interest.
SILVER SPRING, MD. – Without power morcellation, the number of hysterectomies performed using an open approach would dramatically increase – and the combined mortality from laparoscopic hysterectomy and potential dissemination of leiomyosarcoma would be less than that of open hysterectomy, according to testimony given July 11 at a Food and Drug Administration expert panel meeting.
Dr. Jubilee Brown, director of gynecologic oncology at the Woman's Hospital of Texas, University of Texas M.D. Anderson Cancer Center, Houston, testified at the meeting on behalf of the AAGL, an association that promotes minimally invasive gynecologic surgery. She presented results of a decision analysis suggesting that if all U.S. cases were converted to open hysterectomy from laparoscopic hysterectomy (LH) with morcellation of fibroids, 17 more women each year would die from the open procedure than from the combination LH and morcellation.
"Improve – but do not abandon – power morcellation," Dr. Brown told the FDA Obstetrics and Gynecology Devices Advisory Committee. She discussed her testimony during this video interview.
Dr. Brown said she had no relevant financial conflicts of interest.
SILVER SPRING, MD. – Without power morcellation, the number of hysterectomies performed using an open approach would dramatically increase – and the combined mortality from laparoscopic hysterectomy and potential dissemination of leiomyosarcoma would be less than that of open hysterectomy, according to testimony given July 11 at a Food and Drug Administration expert panel meeting.
Dr. Jubilee Brown, director of gynecologic oncology at the Woman's Hospital of Texas, University of Texas M.D. Anderson Cancer Center, Houston, testified at the meeting on behalf of the AAGL, an association that promotes minimally invasive gynecologic surgery. She presented results of a decision analysis suggesting that if all U.S. cases were converted to open hysterectomy from laparoscopic hysterectomy (LH) with morcellation of fibroids, 17 more women each year would die from the open procedure than from the combination LH and morcellation.
"Improve – but do not abandon – power morcellation," Dr. Brown told the FDA Obstetrics and Gynecology Devices Advisory Committee. She discussed her testimony during this video interview.
Dr. Brown said she had no relevant financial conflicts of interest.
AT AN FDA ADVISORY COMMITTEE MEETING
VIDEO: Public testimony gets heated at FDA panel meeting on morcellation
SILVER SPRING, MD. – Power morcellation devices should be never used for gynecologic procedures, Dr. Hooman Noorchashm testified to a Food and Drug Administration expert panel on July ll.
He called out members of the FDA Obstetrics and Gynecology Devices Panel Advisory Committee by name, seeking to shame them into action to disallow power morcellation for suspected uterine fibroids.
"Is this a safe and logical device?" said Dr. Noorchashm, a cardiothoracic surgeon at Brigham and Women’s Hospital in Boston. "The only classification for this device is banned – unsafe, illogical, incorrect, and deadly."
Dr. Noorchashm’s wife, Dr. Amy Reed, had a hysterectomy with morcellation for suspected fibroids. Biopsy later confirmed sarcoma was present. Use of power morcellation caused tumor cells to spread, upstaging her sarcoma to stage IV.
On Twitter @denisefulton
SILVER SPRING, MD. – Power morcellation devices should be never used for gynecologic procedures, Dr. Hooman Noorchashm testified to a Food and Drug Administration expert panel on July ll.
He called out members of the FDA Obstetrics and Gynecology Devices Panel Advisory Committee by name, seeking to shame them into action to disallow power morcellation for suspected uterine fibroids.
"Is this a safe and logical device?" said Dr. Noorchashm, a cardiothoracic surgeon at Brigham and Women’s Hospital in Boston. "The only classification for this device is banned – unsafe, illogical, incorrect, and deadly."
Dr. Noorchashm’s wife, Dr. Amy Reed, had a hysterectomy with morcellation for suspected fibroids. Biopsy later confirmed sarcoma was present. Use of power morcellation caused tumor cells to spread, upstaging her sarcoma to stage IV.
On Twitter @denisefulton
SILVER SPRING, MD. – Power morcellation devices should be never used for gynecologic procedures, Dr. Hooman Noorchashm testified to a Food and Drug Administration expert panel on July ll.
He called out members of the FDA Obstetrics and Gynecology Devices Panel Advisory Committee by name, seeking to shame them into action to disallow power morcellation for suspected uterine fibroids.
"Is this a safe and logical device?" said Dr. Noorchashm, a cardiothoracic surgeon at Brigham and Women’s Hospital in Boston. "The only classification for this device is banned – unsafe, illogical, incorrect, and deadly."
Dr. Noorchashm’s wife, Dr. Amy Reed, had a hysterectomy with morcellation for suspected fibroids. Biopsy later confirmed sarcoma was present. Use of power morcellation caused tumor cells to spread, upstaging her sarcoma to stage IV.
On Twitter @denisefulton
AT AN FDA ADVISORY COMMITTEE MEETING
VIDEO: Lasers – The scar treatment tools you already have
DANA POINT, CALIF. – When you think of lasers, do you consider them as the standard of care for treatment of a range of scars, from dog bites to burns? If not, Dr. Jill Waibel, director of the Miami Dermatology and Laser Institute, thinks you should.
"The sooner you get the lasers on the scars, the better," she emphasizes in this video, recorded during Summit in Aesthetic Medicine 2014. "They [lasers] are both preventative and therapeutic."
Dermatologists can combine lasers and medications that they already have in their practices to great effect to help make scars nearly invisible, Dr. Waibel explained at the meeting, held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed that she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
DANA POINT, CALIF. – When you think of lasers, do you consider them as the standard of care for treatment of a range of scars, from dog bites to burns? If not, Dr. Jill Waibel, director of the Miami Dermatology and Laser Institute, thinks you should.
"The sooner you get the lasers on the scars, the better," she emphasizes in this video, recorded during Summit in Aesthetic Medicine 2014. "They [lasers] are both preventative and therapeutic."
Dermatologists can combine lasers and medications that they already have in their practices to great effect to help make scars nearly invisible, Dr. Waibel explained at the meeting, held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed that she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
DANA POINT, CALIF. – When you think of lasers, do you consider them as the standard of care for treatment of a range of scars, from dog bites to burns? If not, Dr. Jill Waibel, director of the Miami Dermatology and Laser Institute, thinks you should.
"The sooner you get the lasers on the scars, the better," she emphasizes in this video, recorded during Summit in Aesthetic Medicine 2014. "They [lasers] are both preventative and therapeutic."
Dermatologists can combine lasers and medications that they already have in their practices to great effect to help make scars nearly invisible, Dr. Waibel explained at the meeting, held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed that she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
EXPERT ANALYSIS FROM THE SUMMIT IN AESTHETIC MEDICINE
VIDEO: Stems cells may offer more equipoise in traumatic scar treatment
DANA POINT, CALIF. – It’s possible that burn victims and others with traumatic scarring will no longer need to have skin grafted from one part of their body, thus adding new scars, to mend the deeper scars, according to Dr. Jill Waibel, a speaker at Summit in Aesthetic Medicine 2014.
"As surgeons, we don’t have the right to take healthy tissue and create more scars," said Dr. Waibel, director of the Miami Dermatology and Laser Institute and a voluntary clinical professor of dermatology at the University of Miami.
Dr. Waibel and her colleagues are working with the Department of Defense to study whether stem cells can be applied directly to wounds to facilitate new skin tissue growth in service personnel with traumatic injuries from bomb blasts they suffered while fighting in Afghanistan.
She and her team also have been working with the DOD to refine the delivery system for these stem cells, using lasers and a hydrogel developed by the military that can used safely in vivo. Dr. Waibel discusses her hopes and concerns for stem cell use in traumatic scar treatment in this video from the meeting, which was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
DANA POINT, CALIF. – It’s possible that burn victims and others with traumatic scarring will no longer need to have skin grafted from one part of their body, thus adding new scars, to mend the deeper scars, according to Dr. Jill Waibel, a speaker at Summit in Aesthetic Medicine 2014.
"As surgeons, we don’t have the right to take healthy tissue and create more scars," said Dr. Waibel, director of the Miami Dermatology and Laser Institute and a voluntary clinical professor of dermatology at the University of Miami.
Dr. Waibel and her colleagues are working with the Department of Defense to study whether stem cells can be applied directly to wounds to facilitate new skin tissue growth in service personnel with traumatic injuries from bomb blasts they suffered while fighting in Afghanistan.
She and her team also have been working with the DOD to refine the delivery system for these stem cells, using lasers and a hydrogel developed by the military that can used safely in vivo. Dr. Waibel discusses her hopes and concerns for stem cell use in traumatic scar treatment in this video from the meeting, which was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
DANA POINT, CALIF. – It’s possible that burn victims and others with traumatic scarring will no longer need to have skin grafted from one part of their body, thus adding new scars, to mend the deeper scars, according to Dr. Jill Waibel, a speaker at Summit in Aesthetic Medicine 2014.
"As surgeons, we don’t have the right to take healthy tissue and create more scars," said Dr. Waibel, director of the Miami Dermatology and Laser Institute and a voluntary clinical professor of dermatology at the University of Miami.
Dr. Waibel and her colleagues are working with the Department of Defense to study whether stem cells can be applied directly to wounds to facilitate new skin tissue growth in service personnel with traumatic injuries from bomb blasts they suffered while fighting in Afghanistan.
She and her team also have been working with the DOD to refine the delivery system for these stem cells, using lasers and a hydrogel developed by the military that can used safely in vivo. Dr. Waibel discusses her hopes and concerns for stem cell use in traumatic scar treatment in this video from the meeting, which was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.
Dr. Waibel disclosed she has financial relationships with Alma, Syneron/Candela, Sciton, Lutronics, and Lumenis.
On Twitter @whitneymcknight
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
EXPERT ANALYSIS FROM THE SUMMIT IN AESTHETIC MEDICINE
Extending Therapy for Breast Cancer
For more presentations from the 9th Annual Meeting of the Association of VA Hematology/Oncology (AVAHO), click here: AVAHO Meeting Presentations
For more presentations from the 9th Annual Meeting of the Association of VA Hematology/Oncology (AVAHO), click here: AVAHO Meeting Presentations
For more presentations from the 9th Annual Meeting of the Association of VA Hematology/Oncology (AVAHO), click here: AVAHO Meeting Presentations
VIDEO: Does obesity’s effect on RA support different treatment goals?
PARIS – Treat-to-target goals for obese patients with rheumatoid arthritis should take into account new research indicating that they already have a higher level of systemic inflammation and higher Disease Activity Scores than do normal-weight patients, according to Dr. Christopher Sparks of the University of Liverpool, England.
In an international sample of 3,534 patients with rheumatoid arthritis (RA), Dr. Sparks and his colleagues found that those with a body mass index of 30-34.9 kg/m2 (obese) or 35 kg/m2 or greater (obese II) had higher 28-joint Disease Activity Scores (DAS28) than did normal-weight patients, a difference that was largely driven by higher erythrocyte sedimentation rates and higher Visual Analog Scale scores, rather than higher tender and swollen joint counts. The data were reported at the annual European Congress of Rheumatology.
It cannot be known whether obese patients with higher DAS28 scores have clinically more severe disease, so it leads one to wonder, "Is it just an inflated DAS28 score that’s really driving this? And so potentially it brings up the question, Is obesity a confounding factor when looking at DAS28 scores in the RA population?" Dr. Sparks said in a video interview with Dr. Christian Beyer of the University of Erlangen-Nuremberg, Germany.
"If there is an artificial rise in the DAS28 in all of our obese patients out there, should the treatment goals in terms of remission or response be potentially slightly different for obese patients, compared to normal-weight patients, because they have a baseline higher DAS28?"
PARIS – Treat-to-target goals for obese patients with rheumatoid arthritis should take into account new research indicating that they already have a higher level of systemic inflammation and higher Disease Activity Scores than do normal-weight patients, according to Dr. Christopher Sparks of the University of Liverpool, England.
In an international sample of 3,534 patients with rheumatoid arthritis (RA), Dr. Sparks and his colleagues found that those with a body mass index of 30-34.9 kg/m2 (obese) or 35 kg/m2 or greater (obese II) had higher 28-joint Disease Activity Scores (DAS28) than did normal-weight patients, a difference that was largely driven by higher erythrocyte sedimentation rates and higher Visual Analog Scale scores, rather than higher tender and swollen joint counts. The data were reported at the annual European Congress of Rheumatology.
It cannot be known whether obese patients with higher DAS28 scores have clinically more severe disease, so it leads one to wonder, "Is it just an inflated DAS28 score that’s really driving this? And so potentially it brings up the question, Is obesity a confounding factor when looking at DAS28 scores in the RA population?" Dr. Sparks said in a video interview with Dr. Christian Beyer of the University of Erlangen-Nuremberg, Germany.
"If there is an artificial rise in the DAS28 in all of our obese patients out there, should the treatment goals in terms of remission or response be potentially slightly different for obese patients, compared to normal-weight patients, because they have a baseline higher DAS28?"
PARIS – Treat-to-target goals for obese patients with rheumatoid arthritis should take into account new research indicating that they already have a higher level of systemic inflammation and higher Disease Activity Scores than do normal-weight patients, according to Dr. Christopher Sparks of the University of Liverpool, England.
In an international sample of 3,534 patients with rheumatoid arthritis (RA), Dr. Sparks and his colleagues found that those with a body mass index of 30-34.9 kg/m2 (obese) or 35 kg/m2 or greater (obese II) had higher 28-joint Disease Activity Scores (DAS28) than did normal-weight patients, a difference that was largely driven by higher erythrocyte sedimentation rates and higher Visual Analog Scale scores, rather than higher tender and swollen joint counts. The data were reported at the annual European Congress of Rheumatology.
It cannot be known whether obese patients with higher DAS28 scores have clinically more severe disease, so it leads one to wonder, "Is it just an inflated DAS28 score that’s really driving this? And so potentially it brings up the question, Is obesity a confounding factor when looking at DAS28 scores in the RA population?" Dr. Sparks said in a video interview with Dr. Christian Beyer of the University of Erlangen-Nuremberg, Germany.
"If there is an artificial rise in the DAS28 in all of our obese patients out there, should the treatment goals in terms of remission or response be potentially slightly different for obese patients, compared to normal-weight patients, because they have a baseline higher DAS28?"
AT THE EULAR CONGRESS 2014
